ibusinesslines.com March 24, 2018

FDA Approves 1st Home Test for Breast Cancer Genes

07 March 2018, 04:15 | Melissa Porter

A 23and Me kit Lydia Ramsey Business Insider

23andMe kit

The newly authorized test identifies three of 1000-plus mutations associated with breast cancer risk. No doctor's prescription will be needed for the test. These three mutations, however, are not the most common BRCA1/BRCA2 mutations in the general population.

The test is fairly straightforward.

The test analyzes DNA collected from a self-collected saliva sample, and the report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer.

So, while it is unclear what policy shift caused the FDA's recent change of heart, the announcement it published is jam-packed with caveats, highlighting the limitations of 23andme's now approved DTC test.

"The test only detects three out of more than 1,000 known BRCA mutations".

Of course, the test shouldn't be taken as the be all, end all of cancer risk - nor is it meant as a replacement for a proper screening.

"This test provides information to certain individuals who may be at increased breast, ovarian or prostate cancer risk and who might not otherwise get genetic screening, and is a step forward in the availability of [direct-to-consumer] genetic tests".

The approval comes four years after the FDA threw the brakes on 23andMe's race across the consumer genetic testing landscape in a November 2013 warning letter that amounted to a cease-and-desist order.

Around one in 400 people have BRCA mutations that can cause cancer, and is more common among those with eastern European or Jewish descent. The American Cancer Society says this year, it will be diagnosed in 260,000 women and a few men, and will kill almost 41,000.

The FDA today granted authorization for a direct-to-consumer test for a highly selected group of cancer-associated BRCA mutations.

According to the National Cancer Institute, the three mutations are present in ~2% of Ashkenazi Jewish women compared to 0 - 0.1% in other populations.

"For some people who might be getting this test, it might be hard for people to interpret and understand those results".

The FDA says the test is not a substitute for regular medical checkups and should not be used to make any medical decisions. The agency also outlined special controls created to assure test's accuracy and reliability.

Other News

Trending Now

Roger Stone didn't ask for ex-Trump aide Sam Nunberg's protection
Second, Nunberg is a media gadfly, perhaps a personally troubled one, but the Russian Federation investigation is deadly serious. Of the interviews, Tapper's was the best, most incisive - it walked the line between close questioning and polite skepticism.

Help deputies track down man who punched a father holding his child
The 31-year-old has been arrested and charged with first-degree assault, second-degree assault and child abuse. He is being held in the Jefferson County Jail. "He has been described as white, 5" 8 and aged in his mid-20s.

Putin: Russians Charged in Election Meddling 'May Be Brought to Justice'
US spy chiefs have told 21 states they WERE targeted by Putin's hackers before the 2016 US Presidential election. Putin is seeking a fourth term and faces no significant opposition in the March 18 election.

Top US intel official insists White House engaged on election security
Democrats also have criticized Trump for not doing more to punish Russian Federation for its activities during the 2016 election. Russian intelligence and security services are expected to continue to probe USA and allied critical infrastructures next year.

Sebastian Vettel of Ferrari quickest as F1 testing resumes in Spain
Kevin Magnussen did not improve on his morning time, which was good enough for the Haas driver to end the day sixth-fastest. In the afternoon the McLaren's lap tally rose to 38 before a hydraulic issue brought the MCL33 to a halt at Turn 3.

NBA Predictions: Will Pelicans vs. Clippers Matchup Cover the Over? 3/6/18
However, the Clippers had other plans in mind, surging immediately after the quarter started, tying the game with 5:23 to play. Okafor back: Pelicans center Emeka Okafor back in the lineup after missing Sunday's win over Dallas with a sprained ankle.

Trump on EU Trade Threat: 'They Can Do Whatever They'd Like'
He has heavily backed the steel and aluminum tariffs in recent days. "Believe me, everybody wants to work in the White House". Trump is citing his power to impose limits on commodities necessary for national security.